Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (161-170 of 225) with videos related to

Pageof 23
Sort By:
JCO Oncology Practice|May 27, 2020
Management of Lung Cancer During the COVID-19 PandemicAditi P Singh, Abigail T Berman, Melina E Marmarelis, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 studyShirish M Gadgeel, James P Stevenson, Corey J Langer, et al.
Cancer|October 21, 2018
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs dataJoshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2014
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancerCorey J Langer, Istvan Albert, Helen J Ross, et al.
The Oncologist|May 15, 2023
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung CancerCharu Aggarwal, Alisha P Maity, Joshua M Bauml, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2010
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibitionAntonio Gualberto, Marisa Dolled-Filhart, Mark Gustavson, et al.
Clinical Lung Cancer|December 6, 2020
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based TherapyLova Sun, Christiana W Davis, Wei-Ting Hwang, et al.
JCO Precision Oncology|February 16, 2019
Influence of <i>TP53</i> Mutation on Survival in Patients With Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerCharu Aggarwal, Christiana W Davis, Rosemarie Mick, et al.
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLCCorey J Langer, Edward S Kim, Eric C Anderson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Pageof 23

Showing results (161-170 of 225) with videos related to

Sort By:
Pageof 23
JCO Oncology Practice|May 27, 2020
Management of Lung Cancer During the COVID-19 PandemicAditi P Singh, Abigail T Berman, Melina E Marmarelis, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 studyShirish M Gadgeel, James P Stevenson, Corey J Langer, et al.
Cancer|October 21, 2018
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs dataJoshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2014
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancerCorey J Langer, Istvan Albert, Helen J Ross, et al.
The Oncologist|May 15, 2023
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung CancerCharu Aggarwal, Alisha P Maity, Joshua M Bauml, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2010
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibitionAntonio Gualberto, Marisa Dolled-Filhart, Mark Gustavson, et al.
Clinical Lung Cancer|December 6, 2020
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based TherapyLova Sun, Christiana W Davis, Wei-Ting Hwang, et al.
JCO Precision Oncology|February 16, 2019
Influence of <i>TP53</i> Mutation on Survival in Patients With Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerCharu Aggarwal, Christiana W Davis, Rosemarie Mick, et al.
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLCCorey J Langer, Edward S Kim, Eric C Anderson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Pageof 23